Patents by Inventor Claney Lebev PEREIRA
Claney Lebev PEREIRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891413Abstract: The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—Ux+4—Ux+3—Ux+2—Ux+1—Ux)m—(Vx+2—Vx+1—Vx)1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.Type: GrantFiled: November 30, 2018Date of Patent: February 6, 2024Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Arun Naini, Daniel Knopp, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
-
Publication number: 20230122752Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.Type: ApplicationFiled: August 10, 2022Publication date: April 20, 2023Inventors: Sharavathi Guddehalli Parameswarappa, Marilda P. Lisboa, Sylvia Oestreich, Jessica Przygodda, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
-
Publication number: 20230045939Abstract: The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.Type: ApplicationFiled: November 22, 2019Publication date: February 16, 2023Inventors: Madhu EMMADI, Marilda P. LISBOA, Daniel KNOPP, Bopanna MONNANDA, Arne VON BONIN, Claney Lebev PEREIRA
-
Patent number: 11479574Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.Type: GrantFiled: November 30, 2018Date of Patent: October 25, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Sharavathi Guddehalli Parameswarappa, Marilda P. Lisboa, Sylvia Oestreich, Jessica Przygodda, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
-
Publication number: 20210386845Abstract: The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—Ux+4—Ux+3—Ux+2—Ux+1—Ux)m—(Vx+2—Vx+1—Vx)1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.Type: ApplicationFiled: November 30, 2018Publication date: December 16, 2021Inventors: Arun Naini, Daniel Knopp, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
-
Patent number: 11191822Abstract: The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae.Type: GrantFiled: June 22, 2017Date of Patent: December 7, 2021Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Madhu Emmadi, Sharavathi Guddehalli Parameswarappa, Adam Calow, Petra Menova, Marilda Lisboa, Christopher Martin, Benjamin Schumann, Fei-Fei Xu, Naeem Khan, Paulina Kaplonek, Lennart Lykke
-
Publication number: 20210198304Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.Type: ApplicationFiled: November 30, 2018Publication date: July 1, 2021Inventors: Sharavathi Guddehalli Parameswarappa, Marilda P. Lisboa, Sylvia Oestreich, Jessica Przygodda, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
-
Patent number: 11014952Abstract: The present invention provides a stable synthetic saccharide of Hib polyribosylribitol-phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with Haemophilus influenzae, and more specifically of diseases associated with Haemophilus influenzae type b, preferably diseases selected from meningitis, pneumonia, and epiglotitis. They have general formula (I): wherein A is formula (II) or formula (III); B is formula (IV); C is formula (V); D is formula (VI); E is formula (VII); F is formula (VIII) or formula (IX).Type: GrantFiled: July 28, 2017Date of Patent: May 25, 2021Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Vaxxilon AGInventors: Peter H. Seeberger, Claney Lebev Pereira
-
Patent number: 10864261Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.Type: GrantFiled: December 16, 2016Date of Patent: December 15, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
-
Patent number: 10688169Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.Type: GrantFiled: March 29, 2016Date of Patent: June 23, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
-
Patent number: 10596272Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: January 26, 2016Date of Patent: March 24, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Chakkumkal Anish, Marilda Lisboa, Christopher Martin, Claney Lebev Pereira, Peter H. Seeberger, Naeem Khan
-
Publication number: 20200016257Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.Type: ApplicationFiled: December 16, 2016Publication date: January 16, 2020Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
-
Publication number: 20190240309Abstract: The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae.Type: ApplicationFiled: June 22, 2017Publication date: August 8, 2019Inventors: Peter H. Seeberger, Claney Lebev Pereira, Madhu Emmadi, Sharavathi Guddehalli Parameswarappa, Adam Calow, Petra Menova, Marilda Lisboa, Christopher Martin, Benjamin Schumann, Fei-Fei Xu, Naeem Khan, Paulina Kaplonek, Lennart Lykke
-
Patent number: 10328141Abstract: The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.Type: GrantFiled: July 7, 2014Date of Patent: June 25, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann
-
Publication number: 20190153015Abstract: The present invention provides a stable synthetic saccharide of Hib polyribosylribitol-phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with Haemophilus influenzae, and more specifically of diseases associated with Haemophilus influenzae type b, preferably diseases selected from meningitis, pneumonia, and epiglotitis. They have general formula (I): wherein A is formula (II) or formula (III); B is formula (IV); C is formula (V); D is formula (VI); E is formula (VII); F is formula (VIII) or formula (IX).Type: ApplicationFiled: July 28, 2017Publication date: May 23, 2019Inventors: Peter H. Seeberger, Claney Lebev Pereira
-
Publication number: 20190119313Abstract: The present invention relates to the preparation of a synthetic tetrasaccharide, hexasaccharide and octasaccharide representing part of the repeating unit of the Streptococcus pneumoniae type 3 capsular polysaccharide as well as conjugates thereof. Said conjugates are particularly useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae type 3. The disclosed synthetic method has the huge advantages over the state of the art synthetic methods that intermediate products are crystalline, coupling reaction yields are higher, less reaction steps are required and purification of intermediate products is easier.Type: ApplicationFiled: April 18, 2017Publication date: April 25, 2019Inventors: Peter H. Seeberger, Claney Lebev Pereira, Sharavathi Guddehalli Parameswarappa, Adam Daniel James Calow, Petra Menova, Ju Yuel Baek
-
Patent number: 10220083Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: September 28, 2015Date of Patent: March 5, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
-
Patent number: 10188718Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: May 15, 2015Date of Patent: January 29, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
-
Publication number: 20180296687Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: ApplicationFiled: January 26, 2016Publication date: October 18, 2018Inventors: Chakkumkal ANISH, Marilda LISBOA, Christopher MARTIN, Claney Lebev PEREIRA, Peter H. SEEBERGER, Naeem KHAN
-
Patent number: 10052373Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.Type: GrantFiled: September 18, 2014Date of Patent: August 21, 2018Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Dominea Rathwell, Sharavathi Guddehalli Parameswarappa, Subramanian Govindan, Chakkumkal Anish, Claney Lebev Pereira, Peter H. Seeberger, Felix Bröcker